Hypersensitivity |
101 |
Introduction |
135 |
Pharmacological effects |
102 |
Model construction |
136 |
( carcinogenesis) |
103 |
Model validation |
139 |
Antimicrobial effects |
103 |
Applications |
140 |
Hormonal effects |
105 |
Concluding remarks and future |
|
Carry-over of the feed of coccidiostats and |
directions |
141 |
|
other medicated feed |
106 |
References |
141 |
reference point for action |
108 |
8. Toxicological testing: In vivo and in |
vitro models |
Sensory additives |
114 |
Routes of test compound |
|
Nutritional additives |
114 |
administration |
144 |
Zootechnical additives |
114 |
Reproductive toxicity tests |
146 |
Comparative setting toxicological standards |
Developmental toxicity testing |
146 |
maximum residue limits for drugs and |
Carcinogenicity tests |
148 |
|
feed additives |
115 |
Neurotoxicity |
148 |
Concluding remarks and future |
||
toxicology |
directions |
155 |
References |
157 |
|
Deon van der Merwe and Ronette Gehring |
Introduction |
131 |
9. Toxicoproteomics in diagnostic |
|
Underlying physiology |
132 |
toxicology |
|
|
Absorption
Distribution
|
132
132
|
Christina Wilson-Frank |
|
Biotransformation |
132 |
Introduction |
161 |
Flip-flop kinetics |
135 |
Proteomics applications in diagnostic |
|
Residues |
135 |
toxicology |
165 |